(Q35576075)

8 August 2017

1 reference

title

Chemical modification of proteins by lipids in diabetes (English)

1 reference

8 August 2017

John W Baynes

1

1 reference

8 August 2017

publication date

1 September 2003

1 reference

Clinical Chemistry and Laboratory Medicine

8 August 2017

published in

1 reference

8 August 2017

volume

41

1 reference

8 August 2017

issue

9

1 reference

8 August 2017

page(s)

1159-1165

1 reference

Protein glycation, diabetes, and aging

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Glycoxidation and lipoxidation in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Lipid peroxidation in aging and age-dependent diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

The oxidative modification hypothesis of atherosclerosis: does it hold for humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Amides are novel protein modifications formed by physiological sugars

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Identification and quantification of major maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Advanced glycosylation end products in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Advanced glycation end products and mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Advanced glycation end products in nondiabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Tobacco smoke is a source of toxic reactive glycation products

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

Antibodies to advanced glycation end products in children with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.179

21 January 2018

Identifiers

DOI

10.1515/CCLM.2003.179

1 reference

8 August 2017

1 reference